By Fineline Cube 
XtalPi Inc. (HKG: 2228) and Gan & Lee Pharmaceuticals (SHA: 603087) announced that their jointly established “AI Peptide Delivery Lab” — formally the Beijing Key Laboratory of AI‑Driven Peptide Drug Design and Delivery Systems — has officially received recognition as a “Beijing Key Laboratory,” marking a major step forward as the two companies enter a phase of fully deepened collaboration in AI‑powered peptide drug R&D.
Milestone Overview
| Item | Detail |
|---|---|
| Parties | XtalPi Inc. (HKG: 2228) × Gan & Lee Pharmaceuticals (SHA: 603087) |
| Facility | AI Peptide Delivery Lab (Beijing Key Laboratory of AI‑Driven Peptide Drug Design and Delivery Systems) |
| Recognition | Officially designated a “Beijing Key Laboratory” |
| Announcement Date | 9 Jul 2026 |
| Significance | Signals a fully deepened collaboration phase in AI‑powered peptide drug R&D |
What Beijing Key Laboratory Status Means
As a crucial component of Beijing’s technological innovation system, Beijing Key Laboratories carry strategic missions to:
- Gather top innovative talent in frontier research fields
- Conduct high‑level research with national strategic relevance
- Drive breakthroughs in key technologies critical to industrial competitiveness
The designation places the joint laboratory within Beijing’s official innovation infrastructure, potentially unlocking policy, funding and talent advantages.
Three Core Research Directions
| Research Direction | Focus |
|---|---|
| 1. AI‑Driven Integrated Platform | Building a “virtual screening + wet‑lab validation” platform to advance the design and druggability optimization of peptide molecules for treating chronic metabolic diseases |
| 2. Novel Oral Delivery Systems | Developing next‑generation oral delivery technologies to enhance gastrointestinal stability, transmembrane transport efficiency, and bioavailability of peptide therapeutics |
| 3. Ultra‑Long‑Acting & Sustained‑Release Formulations | Exploring advanced delivery technologies to extend dosing intervals to significantly longer cycles |
Strategic Rationale & Market Impact
- AI × Peptide Convergence: The lab pairs XtalPi’s AI‑driven drug discovery capabilities with Gan & Lee’s established peptide pharmaceutical expertise — a combination targeting one of the industry’s fastest‑growing modality frontiers.
- Chronic Metabolic Disease Opportunity: Peptide therapeutics for chronic metabolic diseases represent a large and expanding market, where improved design and delivery can materially differentiate products.
- Oral Delivery as a Differentiator: Overcoming the gastrointestinal and bioavailability barriers of peptide drugs remains a key industry challenge; success in oral peptide delivery could transform patient compliance and market accessibility.
- Dosing‑Interval Extension: Ultra‑long‑acting formulations with significantly longer dosing cycles would strengthen competitive positioning in chronic care, where convenience drives adherence and commercial uptake.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the laboratory’s research agenda, technology breakthroughs, and downstream product development. Actual results may differ due to risks including research outcomes, regulatory pathways, and competitive dynamics.-Fineline Info & Tech